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Abstract 
Background: In 2017, the Centers for Disease Control and Prevention reviewed and published 
guidelines for prescribing antibiotics. These guidelines emphasized treating acute uncomplicated 
cystitis (AUC) with nitrofurantoin (NTF), sulfamethoxazole-trimethoprim (SMX-TMP), or 
fosfomycin (FM) as appropriate first-line agents. 
Objective: This paper aims to evaluate whether provider adherence to prescribing NTF, SMX-
TMP, or FM has improved since the 2017 CDC guidelines were released. The paper also 
examines patient outcomes in the treatment of AUC in non-pregnant women relative to use of 
prescribing guidelines. 
Methods: A literature review was conducted in compliance with the Preferred Reporting Items 
for Systematic Reviews and Meta-Analysis (PRISMA). The Cochrane Risk of Bias Tool (2020) 
was used to assess publication bias. The John Hopkins Research Evidence Appraisal Tool (John 
Hopkins, 2017) was used to grade the articles. The design, study sample, and major findings of 
each article were identified for their utility in the review of evidence. The outcome 
measurements were as follows: adherence to appropriate prescription of first-line antibiotics for 
the treatment of AUC, improvement or complete resolution of symptoms, bacterial eradication, 
and cost-effectiveness. 
Results: The literature searches in the PubMed and Cochrane databases resulted in 56 published 
studies. The initial review excluded 19 duplicates and 18 other publications that examined 
complicated urinary tract infection and pregnant women. Subsequent reviews further excluded 8 
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publications that were ineligible to meet the objective. After application of exclusion criteria, 11 
peer-reviewed articles were ultimately included in this review. 
Limitations: Publications were still limited since the CDC released a review of the IDSA 2011 
UAC treatment guidelines in 2017. Although published in or after 2017, four of the studies 
included in this paper were retrospective, measuring data from prior to 2017. The studies 
reviewed in this paper assessed bacterial and symptom resolution between 9 and 28 days post-
treatment at the most. 
Conclusion: The review showed prescribers’ increasing awareness of and efforts to adhering to 
antibiotic prescription guidelines in the treatment of AUC, such as the 2011 IDSA guidelines that 
were reviewed and published by the CDC in 2017. With the increasing pattern of adherence, the 
trials, systematic reviews, and meta-analyses included in this study presented strong evidence 
that first-line antibiotics FM, NTF, and SMX-TMP are equally efficacious and cost-effective in 
the treatment of AUC in non-pregnant women without concern for antibiotic resistance. 
 
 
 
 
 
Keywords: Acute uncomplicated cystitis; first-line antibiotics; prescribing guidelines; prescribing 
adherence. 
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Introduction 
 About half of women report symptoms of urinary tract infection (UTI), and one-third 
require antibiotic treatment before they reach the age of 25. UTIs are responsible for a yearly 
occurrence of eight million clinic visits and hospitalizations and an overall annual cost of $2.4 
billion in the United States (Barber, Norton, Spivak, & Mulvey, 2013). However, the 
unnecessary use of antibiotics accounts for the increasing national and global prevalence of 
antibiotic resistance. Therefore, practice guidelines and research have aimed to reduce antibiotic 
use while effectively treating infections, such as UTIs in women.  
In 2017, the Centers for Disease Control (CDC) reviewed and published guidelines for 
prescribing antibiotics. These guidelines emphasized treating acute uncomplicated cystitis 
(AUC) with nitrofurantoin (NTF), sulfamethoxazole-trimethoprim (SMX-TMP; for which local 
resistance is < 20%), or fosfomycin (FM) as appropriate first-line agents. AUC, or acute 
uncomplicated UTI (uUTI), is usually caused by E. coli. Symptoms include dysuria, frequent 
voiding of small volumes, and urinary urgency, while nitrites and leukocyte esterase in urinalysis 
are the most accurate indicators of AUC (CDC, 2017). This paper aims to evaluate whether 
provider adherence to prescribing NTF, SMX-TMP, or FM has improved since the 2017 CDC 
guidelines were released, and evaluate patient outcomes in the treatment of AUC in women 
relative to the prescription adherence. 
Methods 
Search Strategy 
 A literature review was conducted in compliance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA), and a systematic search for articles was 
conducted in the PubMed and Cochrane search engines using Boolean operators (AND, OR). 
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The inclusion criteria included a publication year between 2017 and 2020, text in the English 
language, and articles that were peer-reviewed. The search terms “first-line antibiotics AND 
acute uncomplicated cystitis OR uncomplicated urinary tract infection” and “prescription 
adherence AND first-line antibiotics AND acute uncomplicated cystitis OR uncomplicated 
urinary tract infection” were initially used. The search terms were then modified to “outcomes 
AND first-line antibiotics AND acute uncomplicated cystitis OR uncomplicated urinary tract 
infection.” The search terms resulted in 15 publications from 2017–2020 from both the PubMed 
and Cochrane databases. Additional search terms were “nitrofurantoin AND cystitis,” 
“fosfomycin AND cystitis,” and “sulfamethoxazole-trimethoprim AND cystitis.” 
Data Items  
 Prescriber adherence was measured based on the practitioner’s decision to treat AUC 
with the first-line antibiotics FM, SMX-TMP, or NTF in accordance with the Infectious Disease 
Society of America (IDSA) 2011 guidelines that were reviewed and publicized by the CDC in 
2017. AUC patient outcomes were measured with improved or complete resolution of symptoms 
and/or microbiological response 28 days post-treatment at the most. Classic symptoms of AUC 
include dysuria, frequent voiding of small volumes, and urinary urgency, while nitrites and 
leukocyte esterase are the most accurate indicators in urinalysis. Microbiological response is 
defined as reduced bacterial pathogens in a quantitative urine culture at the test of cure visit post-
treatment. 
Risk of Bias 
 The Cochrane Risk of Bias Tool (2020) was used to assess publication bias (Table 3). Of 
the 11 publications, nine had a low risk of bias, while three of the nine had some concerns with 
randomization. One of the publications had some concerning risk for bias due to lack of 
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identification and measurement of comparable antibiotics. The quasi-experimental study had 
some concerning risk for bias because of possible overlapping interventions.  
Summary Measurements  
  The primary outcome measurement was adherence to appropriate prescription of first-
line antibiotics for the treatment of AUC, as opposed to prescription of fluoroquinolones (FQ) 
and β lactams. Clinicians did not meet adherence if a first-line antibiotic was not prescribed in 
the absence of contraindication showing that the patient did not meet the criteria for first-line 
antibiotic treatment. The secondary outcome measurement was the patients’ outcome as a result 
of prescribing first-line antibiotics, whether improvement or complete resolution of symptoms 
and bacterial eradication in urinalysis. Cost-effectiveness was also an outcome measurement that 
included monetary factors and/or quality-adjusted life-months (QALMs). 
Critical Appraisal Tool 
The John Hopkins Research Evidence Appraisal Tool (John Hopkins, 2017) was used to 
grade the articles (Table 1). High-quality, good-quality, and low-quality ratings were used. 
Studies with consistent results, a sufficient sample size, a definitive conclusion, and consistent 
recommendations with thorough references to scientific evidence were graded as having high 
quality. Studies with reasonably consistent results, a sufficient sample size, an acceptably 
definitive conclusion, and reasonably consistent recommendations with some references to 
scientific proof were graded as having good quality. Studies with limited evidence, inconsistent 
results, a small sample size, and a vague conclusion were graded as having low quality. Table 2 
provides a synthesis of each publication. The design, study sample, and major findings of each 
article were identified for their utility in the review of evidence.  
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Results 
 The literature searches in the PubMed and Cochrane databases resulted in 56 published 
studies (Diagram 1). After initial review, 19 duplicates were excluded. Additionally, 18 other 
publications were excluded, most of which included information on complicated UTI and 
pregnant women. Subsequent reviews further excluded 8 publications that were ineligible to 
meet the objective. After exclusions and inclusion, 11 peer-reviewed articles were included in 
the review: 10 quantitative studies and one qualitative study. Of these, one trial (Huttner et al., 
2018), two systematic reviews and meta-analyses (Mitrani-Gold, Raychaudhuri, & Rao, 2020; 
Cai et al., 2020), and one retrospective study (Pedela et al., 2017) assessed bacterial eradication 
and clinical symptoms treatment with NTF, FM, SMX-TMP, FQ, and β lactams. Two meta-
analyses (Sadler et al., 2017; Perrault, Dahan, Iliza, LeLorier, & Zhanel, 2017) and one 
prospective study (Sanyal, Husereau, Beahm, Smyth, & Tsuyuki, 2019) assessed the cost-
effectiveness of treating AUC with SMX-TMP, NTF, FM, and pivemecillinam. Finally, one trial 
(Robinson, Barsoumian, Aden, & Giancola, 2019), two retrospective studies (Pedela et al., 2017; 
Yu, McKenna, Dumyati, Lubowski, & Carreno, 2020), one quasi-experimental study (Giancola 
et al., 2019), and one semi-structured interview (Grigoryan et al., 2019) assessed clinicians’ 
adherence to prescribing first-line antibiotics (NTF, FM, SMX-TMP) to treat AUC. 
Prescriber Adherence 
 Robinson et al. (2019) evaluated the appropriateness of empiric FQ use compared to NTF 
use for treating AUC and determined trends and predictors for the use of FQ. Women aged 19–
64 who were given NTF, ciprofloxacin, or levofloxacin for AUC at five family medicine clinics 
were included in the study. Data concerning symptoms, comorbidities, allergies, creatinine 
clearance, recent antibiotic use, and urine culture were used to determine if empiric antibiotic 
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treatment was appropriate based on national guidelines and local susceptibility data. Of the 567 
women included in the study, 395 were given NTF and 172 were given FQ. Of these, 343 
(86.8%) and 18 (10.5%) were appropriately prescribed NTF and FQ, respectively. For women 
inappropriately prescribed FQ, 15 (87.8%) lacked contraindication to NTF. Therefore, the study 
suggested the need for additional intervention and education to improve and decrease use of FQ.  
Yu et al. (2020) aimed to track and report outpatient antibiotic prescriptions in Medicare 
Part B older adult enrollees diagnosed with cystitis in an outpatient setting between 2016 and 
2017 in New York state (NYS). Inclusion criteria included oral antibiotic prescription less than 
three days after diagnosis of cystitis in Part D claims. According to the retrospective cohort 
study, 50,658 prescriptions were written upon discharge diagnosis of cystitis in NYS from 2016–
2017. First-line antibiotic prescriptions of NTF, SMX-TMP, and FM as well as β lactamase 
prescriptions increased, and FQ use decreased in both older female and male adults. The study 
suggested that the widespread prevalence of FQ and β lactamase prescriptions requires outpatient 
antimicrobial stewardship.  
Giancola et al. (2019) conducted a quasi-experimental study that included women aged 
18–64 years who were prescribed NTF, SMX-TMP, or ciprofloxacin within seven days of 
encounter at five family medicine clinics. Adherence to duration of treatment (DOT) based on 
IDSA (2011) guidelines was evaluated. Stewardship intervention included revising/adding 
default prescription instructions to targeted antimicrobials in an electronic health record (EHR) 
and a one-day in-service at two (intervention group) of the five clinics. A total of 787 pre-
intervention patients were compared with 862 post-intervention patients. After intervention, the 
adherence rate to the recommended DOT increased from 31% to 89% for NTF and from 22% to 
60% for SMX-TMP. Additionally, adherence to recommended DOT increased in clinics that 
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received education (33.7% vs. 90.2%; p < 0.01); these clinics increased adherence from 22.1% to 
58.8% (p < 0.01). Revising or adding default prescription instructions and their DOT to targeted 
antimicrobials in an EHR and providing clinician in-service also increased adherence to first-line 
antibiotic DOT guidelines.  
Pedela et al. (2017) evaluated changes in outpatient FQ and NFT use and resistance 
among E. coli isolates after a change in institutional guidance to use NFT over FQs for AUC. 
The study compared the period from January 2003 to June 2007, when FQs were recommended 
as a first-line therapy for acute uUTIs, with the period from July 2007 to December 2012, when 
NTF was recommended as the first-line therapy. The retrospective time series study included 
5,714 adults treated for AUC and 11,367 outpatient E. coli isolates. After the change in 
institutional guidelines, FQ use showed an immediate 26% reduction, and FQ-resistant E. coli 
were stabilized. The use of NTF increased without changing NTF resistance.  
Grigoryan et al. (2019) sought to understand why primary care providers (PCPs) choose 
certain antibiotics or durations of treatment and to identify the sources of information guiding 
antibiotic prescription decisions. The study conducted a semi-structured interview with 18 PCPs 
in two family medicine clinics in Texas. Most PCPs reported that they prescribed SMX-TMP or 
NTF, but sometimes for a longer duration than recommended by the IDSA (2011). The PCPs 
also described multiple considerations when prescribing antibiotics, including allergies, sex, 
pregnancy, older age, past antibiotic experience and susceptibilities, familiarity with the 
antibiotic, shorter treatment duration and better compliance, UTI frequency, diabetes, and cost. 
Many PCPs mentioned that NTF was not as “strong” or as “quick” as SMX-TMP, and most were 
unfamiliar with FM. Few PCPs relied directly on guidelines to treat uUTIs; only two recalled and 
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mentioned the IDSA (2011) guidelines. Additionally, the PCPs had widely differing opinions on 
the extent to which antibiotic resistance was a problem in their practice. 
Bacterial Eradication and Symptoms Resolution 
 A retrospective pre/post-intervention study by Pedela et al. (2017) concluded that, with 
the immediate 26% reduction in FQ use from July 2007 to December 2012, FQ-resistant E. coli 
stabilized. Additionally, the non-significant increase in NTF use did not change the pattern of 
NTF-resistant E. coli. The use of oral cephalosporin, which is not a first-line antibiotic for AUC, 
also increased during the post-intervention period. 
Huttner et al. (2018) compared the clinical and microbiological efficacy of NTF and FM 
for treating AUC in women. Their multinational, open-label, analyst-blinded, randomized 
clinical trial examined 513 women aged 18 years and older with symptoms of AUC. The 
participants were recruited at hospital and outpatient units in Geneva, Switzerland, from October 
2013 to April 2017. Of the participants, 255 were randomized to take oral NTF in doses of 100 
mg three times daily for five days, while 258 were randomized to take FM in a single 3-g dose. 
Of these participants, 475 (93%) completed the trial and returned 14 and 28 days after therapy. 
At 28 days, 171 of 244 (70%) of the NTF group and 139 of 241 (58%) of the FM group achieved 
clinical resolution. Microbiologic resolution occurred in 129 of 175 (74%) and 103 of 163 (63%) 
in the NTF and FM groups, respectively. The study concluded that the five-day NTF treatment 
had significantly higher clinical and microbiological resolution than single-dose FM treatment, 
with a few adverse gastrointestinal events of nausea and vomiting for both groups. The study did 
not refer to local antibiotic resistance data and did not include information on treatment with 
SMX-TMP.  
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Cai et al. (2020) performed a systematic review and meta-analysis to compare the 
effectiveness and safety profile, or adverse effects, of FM to those of SMX-TMP, NTF, FQ, and 
β lactams in women with AUC. The study included 15 random controlled trials (RCTs) and 
2,295 adults. Of the studies, 14 that examined a total of 2,052 patients found no difference for 
microbial eradication (OR 1.03, 95% CI 0.83–1.30, p = 0.09). No difference for safety outcomes 
was found in 11 RCTs with a total of 1,816 patients (OR 1.17, 95% CI 0.86–1.58, p = 0.33). FM 
was associated with high patient compliance and was as effective and safe as SMX-TMP, NTF, 
FQ, and β lactams in the treatment of AUC. The study did not mention local antibiotic resistance.  
Mitrani-Gold et al. (2020) conducted a systemic literature review and meta-analysis to 
estimate the treatment effect of NTF. Their analysis included 12 studies, including 11 trials. The 
study estimated the microbiological response rate for NTF and placebo treatments through cross-
trial comparison and interstudy. Heterogeneity was assessed using Cochran’s chi-square test. 
Microbiological response was defined as the reduction of bacterial pathogens to 103 CFU/ml (or 
no growth) in the microbial intent-to-treat population on a quantitative urine culture at the test of 
cure visit, five to nine days post-treatment. The overall microbiological response, with 95% 
confidence interval, was 0.766 (0.665, 0.867) for NTF and 0.342 (0.288, 0.397) for the placebo. 
Therefore, NTF was effective in the treatment of uUTIs with a conservative non-inferiority 
margin of 12.5%, which was consistent with the April 2018 FDA guidance that showed a non-
inferiority margin of 10% (U.S. Food and Drug Administration, 2019). The study did not assess 
SMX-TMP and FM for their microbiological response rate.  
Cost-effectiveness 
  Perrault et al. (2017) performed cost-minimization analysis using a decision tree model 
to compare the cost of treatment per patient in Ontario, Canada. As an option for first-line 
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empirical treatment of uUTIs, the cost of FM was compared with the current cost of treatment 
with sulfonamides, FQ, and NTF. All four antibiotics were found to be equally cost-effective. 
Sadler et al. (2017) assessed the relative cost-effectiveness of SMX-TMP, FM, NTF, and 
pivmecillinam, which are currently recommended in England for treatment of uUTIs in adult 
women. Cost-effectiveness was assessed as cost per resolved UTI. The study aimed to guide 
clinicians in their empirical prescribing choice based on cost-effectiveness and local resistance 
levels. Actual prescribing practices varied between local areas. NTF was prescribed more than 
2.3 million times in 2015. Prescribing SMX-TMP was still common despite evidence of high 
local resistance. The following treatments were the most effective for resolution (approx. 850 
cases resolved per 1000) and had the lowest total cost: trimethoprim given in a 200-mg dose 
twice daily for seven days, FM given in a single 3-g dose, and NTF given in a 100-mg dose 
twice daily for seven days. Trimethoprim was estimated to be the most cost-effective treatment 
when resistance was < 30%. If resistance to trimethoprim was > 30%, then FM and NTF were 
the most cost-effective. These three antibiotics had the lowest total cost.  
Sanyal et al. (2019) calculated the costs of antibiotic treatment and health services based 
on cost data from Canada. A probabilistic analysis was used to evaluate the impact 
of treatment strategies on costs and QALMs. Management of uUTIs by community pharmacists 
in Canada resulted in high cure rates and a high degree of patient satisfaction. Using prescribing 
guidelines, community pharmacists in New Brunswick, Canada, prescribed NTF, SMX-TMP, 
and FM in 88%, 8%, and 2% of cases, respectively, while physicians prescribed NTF, SMX-
TMP, and FM in 55%, 26%, and 2% of cases, respectively. All patients were assumed to achieve 
resolution of symptoms in one month, including those who received a second round of treatment. 
The mean costs of community pharmacist, family physician, and emergency physician-initiated 
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management were $72.47, $141.53, and $368.16, respectively. The mean QALMs of pharmacist, 
family physician, and emergency physician-initiated management were 0.75137, 0.75142, and 
0.75146, respectively. Therefore, the community pharmacist-initiated and guided management 
was less costly and provided comparable QALMs compared to that initiated by family and 
emergency physicians when prescribing NTF, SMX-TMP, or FM to treat uUTIs.  
Discussion 
Summary of Evidence  
 All 11 studies, which included trials, systemic reviews and meta-analyses, retrospective 
studies, a quasi-experimental study, and a semi-structured interview study, were high quality and 
presented strong evidence of their findings. The 10 quantitative studies used robust statistical 
analysis to measure outcomes. Sadler et al. (2017) and Perrault et al. (2017) assessed cost-
effectiveness with reference to local antibiotic resistance levels. Robinson et al. (2019), Giancola 
et al. (2019), and Pedela et al. (2017) assessed prescription adherence with reference to local 
antibiotic resistance. Giancola et al. (2019) assessed prescriber adherence with reference to IDSA 
(2011) guidelines for DOT and local antibiotic resistance. No bias secondary to funding was 
found. 
 The two systematic reviews and meta-analyses, one trial, and one retrospective study 
(Mitrani-Gold et al., 2020; Cai et al., 2020; Huttner et al., 2018; Pedela et al., 2017) concluded 
that FM, SMX-TMP, and NTF were equally effective for microbiological and symptom 
resolution of AUC 9–28 days after treatment. Fosfomycin trometamol was associated with high 
patient compliance. Trimethoprim, FM, and NTF had the lowest total cost. SMX-TMP was 
estimated to be the most cost-effective treatment when local resistance was < 30%. If resistance 
to SMX-TMP was > 30%, a single 3-g dose of FM or a twice-daily, 100-mg dose of NTF for 
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seven days was the most cost-effective treatment. The uUTI management guided by community 
pharmacists in Canada yielded high cure rates, lower costs, and comparable QALMs compared 
to management guided by family and emergency physicians when prescribing NTF, SMX-TMP, 
or FM (Sanyal et al., 2019). 
 Of the 11 publications, five showed that the lack of institutional guidelines yielded poor 
adherence in prescribing first-line antibiotics to treat AUC. The qualitative study suggested that 
few providers relied on the IDSA (2011) guidelines to treat uUTIs, and most providers described 
multiple factors in their decision-making when prescribing antibiotics, such as age, past 
antibiotic experience, shorter treatment, and familiarity with antibiotics. The FQ versus NTF 
study by Pedela et al. (2017) stated that the 87.8% women inappropriately prescribed FQ had a 
lack of contraindication to NTF. According to Giancola et al. (2019), revising or adding EHR 
default prescription instructions and their DOT, as well as clinician in-service, increased 
adherence to first-line antibiotic prescriptions. The study by Yu et al. (2020) tracked NYS 
adherence to CDC guidelines concerning the use of first-line antibiotics. Although the study 
reported increased prescriptions of first-line antibiotics and β lactams and decreased use of FQ, 
the study did not mention whether prescribers used institutional guidelines to determine their 
choice of antibiotics. 
Limitations 
This paper included peer-reviewed studies from 2017 to February 2020, but publications 
are still limited since the CDC released its review of the IDSA 2011 AUC treatment guidelines. 
Additionally, although published in or after 2017, four of the studies included in this paper were 
retrospective, measuring data from prior to 2017. Finally, the studies reviewed in this paper 
assessed bacterial and symptom resolutions at 9–28 days post-treatment at the most. 
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Conclusion 
 Since the 2017 CDC AUC treatment guidelines were released, there have not been 
enough studies to assess increased prescriber adherence to using first-line antibiotic in the 
treatment of AUC. Out of the 11 studies included in this paper, 10 showed the prescribers’ 
increasing awareness of and efforts to adhere to antibiotic prescription guidelines, such as the 
2011 IDSA guidelines that were reviewed and published by the CDC in 2017. With the 
increasing pattern of adherence, the trials, systematic reviews, and meta-analyses in this study 
presented strong evidence that first-line antibiotics FM, NTF, and SMX-TMP are equally cost-
effective and efficacious in the treatment of AUC in non-pregnant women, without concern for 
antibiotic resistance. Studies who referenced to prescription guidelines in the use of first-line 
antibiotics and local antibiotic resistance yielded desired patient outcomes in terms of bacterial 
and symptom resolution and cost-effectiveness. 
 Institutional AUC treatment management guidelines embedded in EHR could increase 
prescriber adherence to using first-line antibiotics. Institutional management guidelines should 
include FM, NTF, and SMX-TMP as first-line antibiotics, as well as local antibiotic 
susceptibility or antibiograms and DOTs in the presence of other deciding factors, such as 
comorbidities and older age. Clinicians should also be informed of positive patient outcomes as a 
result of their adhering to appropriate antibiotic prescription practices. This paper suggests 
further studies to quantify prescriber adherence to the 2011 IDSA and 2017 CDC guidelines. 
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Appendix 
Diagram 1 
Reviews based on Prisma diagram 
 
PRISMA 2009 Flow Diagram© 
 
Criteria: Literature in English, published between 2017-February 21, 2020, meeting medical 
search terms. 
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https://www.cochranelibrary.com/advanced-search 
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PubMed 
https://pubmed.ncbi.nlm.nih.gov/ 
(n = 31) 
Records after duplicates removed 
n56- 19duplicates = 37 
(n = 37) 
Records screened 
n=37 
(n =   ) 
Records excluded 
(n =18) 
2 recurrent cystitis 
1 green tea treatment 
1 kidney transplant 
3 pregnant women 
1 cefditoren pivoxil 
1 uroprofit, chronic cystitis 
1 phytotherapeutic med 
1 overactivity/incontinence 
1 mecillinenam 
1 complicated cystitis (DM) 
1 article not available 
4 no full text available 
 
Full-text articles assessed 
for eligibility 
(n=19) 
 
 
Full-text articles excluded,  
with reasons 
(n = 8) 
1 Not specific to prescribing first-line 
antibiotics. 
1 Cepodoxime study 
1 recurrent infection and MDR 
1 Urine culture cost effectiveness 
1 Generic vs brand name antibiotics 
1 pharmacokinetics of 
nitrofurantoin 
1 Guideline review 
1 Guideline Update 
 
 
 
Studies included in 
qualitative synthesis 
(n = 1) 
Studies included in 
quantitative synthesis  
(n = 10) 
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Table 1 
Evaluation Table for Critical Appraisal  
Citation Conceptual 
Framework 
Design/Method Sampling/Setting Major 
variables 
studied and 
their 
definitions 
Measurement 
of Major 
Variables 
Data Analysis Major 
Findings 
Appraisal 
of Worth to 
Practice 
Cost-
Effectiveness 
Analysis of 
Fosfomycin for 
Treatment of 
Uncomplicated 
Urinary Tract 
Infections in 
Ontario. 
Perrault L, et al. 
(2017) 
Decision-
Tree Model 
(Tree Age 
Pro 2015 
software) 
Cost-
minimization 
analysis, meta-
analysis 
Data were 
obtained from 
Physician 
Services (2016), 
Ontario Case 
Costing 
Initiative, and 
Pharma Stat 
provincial data. 
Costs- 
province-level 
data on drug 
cost 
 
Probabilities- 
probabilities 
of resistance, 
effectiveness 
Cost was 
computed based 
on prices in the 
Ontario Drug 
Benefit 
Formulary and 
the 
recommended 
dosage for 
uUTIs. 
 
Probabilities for 
effectiveness 
were assumed 
to be equal for 
all antibiotics 
based on meta-
analysis by 
Falagas et al. 
(2010).  
  
Cost-
minimization 
analysis, meta-
analysis 
 
Resistance rates 
for fosfomycin 
were obtained 
from 
Antimicrobial 
Resistance 
Epidemiological 
Survey on 
Cystitis. 
The analysis 
revealed that 
the cost per 
patient for 
uncomplicated 
UTI treatment 
is similar for 
all 4 
antibiotics, 
from $96.19 
for 
sulfonamides 
to $105.12 for 
fosfomycin. 
Fosfomycin 
has lower 
resistance 
profile, safe, 
effective and 
offers a single 
dose regimen 
for treatment 
of uUTI and is 
associated 
with high 
degree of 
compliance. 
Good 
Cost-
effectiveness of 
antibiotic 
treatment of 
uncomplicated 
urinary tract 
infection in 
women: a 
comparison of 
four antibiotics. 
Sadler S, et al. 
(2017) 
Decision tree 
economic 
model 
updated to 
include UK-
specific 
costs. 
Systems review, 
network meta-
analysis 
 
Probabilistic 
economic and 
deterministic 
sensitivity 
analyses. 
 
  
The systemtatic 
review identified 
11 studies that 
formed a 
connected 
evidence network 
meta-analysis. 
Clinical 
effectiveness- 
clinical cure 
rates in 16 
days, including 
two treatment 
courses. 
 
Cost 
effectiveness 
was assessed 
as cost per UTI 
resolved, and 
based on local 
resistance level 
 
The outcome 
was cost per 
UTI resolved 
Clinical cure 
rates were 
informed by a 
systemic 
review and 
network meta-
analysis. 
Trimethoprim 
200 mg twice 
daily for 3 or 
7days was 
estimated to be 
the most cost-
effective 
treatment when 
resistance 
was<30%. If 
resistance to 
trimethoprim 
was > 30%, 
fosfomycin 3g 
once and 
nitrofurantoin 
100 mg twice 
daily for 7days 
were most cost-
effective. 
Based on 
recent 
estimates of 
trimethoprim 
resistance 
rates in 
England, a 
single 3 g dose 
of Fosfomycin 
is likely the 
most cost-
effective 
treatment 
option for 
uncomplicated 
UTIs in 
women.   
High 
Cost-
effectiveness 
and budget 
impact of the 
management of 
uncomplicated 
urinary tract 
infection by 
A decision 
analytic 
model was 
used to 
compare 
costs and 
outcome of 
community 
Prospective 
Study of 
community 
pharmacists in 
New 
Brunswick, 
Canada between 
Cure rates and 
utilities were 
derived from 
published studies. 
Cost of antibiotic 
treatment and 
health services 
use were 
Pharmacist 
services- 
pharmacists 
prescribing for 
women 
presenting with 
uncomplicated 
UTI 
Cost-
effectiveness 
 
Sensitivity to 
cure rates 
 
Using 
prescribing 
guidelines, 
community 
pharmacist in 
New 
Brunswick, 
Canada 
The 
community 
pharmacist-
initiated and 
guided 
management 
was less costly 
and gave 
High 
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community 
pharmacists. 
Sanyal et al. 
(2019) 
pharmacist-
initiated 
management 
of 
uncomplicate
d UTI to 
family or 
emergency 
physician-
initiated 
management. 
June 2017 and 
April 2018. 
 
Probabilistic 
analysis to 
evaluate impact 
of treatment 
strategies on 
cost and 
quality-
adjusted-life-
months 
(QALMS) 
 
Cost-utility 
analysis 
calculated based 
on cost data from 
Canada.  
 
There was no 
population 
sampling 
mentioned in this 
study. 
 
Pharmacist-
initiated- 
community 
pharmacist 
assessed and 
prescribed 
antibiotics, 
following 
guidelines, to 
women 
presenting with 
uncomplicated 
UTI. 
 
Physician 
initiated- 
physician 
prescribed 
antibiotics to 
women 
presenting with 
uncomplicated 
UTI. 
Societal 
perspective 
prescribed more 
pharmacist 
prescribed 88%, 
8% and 2% of 
Nitrofurantoin, 
TMP-SMX, and 
Fosfomycin 
respectively, 
while 
physicians 
prescribed 55%, 
26%, and 2% of 
Nitrofurantoin, 
TMP-SMX, and 
Fosfomycin 
respectively. All 
patients were 
assumed to 
achieve 
resolution of 
symptoms in 
one month 
including those 
who received 
second round of 
treatment. 
comparable 
QALMs 
compared to 
family and 
emergency 
physicians in 
prescribing 
Nitrofurantoin, 
TMP-SMX, or 
Fosfomycin 
for the 
treatment of 
uncomplicated 
UTIs. 
Qualitative 
Analysis of 
Primary Care 
Provider 
Prescribing 
Decisions for 
Urinary Tract 
Infections 
Grigoryan  et al.  
(2019) 
Mapping and 
sequencing 
behaviors, 
using the 
Cabana 
framework 
which 
includes 
knowledge, 
attitudes, and 
external 
factors.  
Qualitative 
semi-structured 
interviews and 
thematic 
analysis 
18 primary care 
providers 
practicing in two 
family medicine 
clinics in a large 
urban area in 
Texas, between 
July 2017 and 
November 2017. 
Providers’ 
knowledge, 
attitudes, and 
external factors 
Thematic 
analysis 
identified seven 
themes related 
to providers’ 
prescribing 
decisions for 
acute cystitis. 
Most providers 
reported they 
would 
prescribed 
TMP-SMX or 
Nitrofurantoin 
but sometimes 
longer duration 
than 
recommended 
by the 2010 
Infectious 
Disease Society 
of America 
(IDSA); 
providers 
described 
multiple 
consideration 
when 
prescribing 
antibiotics; 
many providers 
mentioned that 
Nitrofurantoin 
is not as 
“strong” and not 
as “quick”; 
most providers 
were unfamiliar 
with 
Fosfomycin; 
few providers 
directly relied 
on guidelines; 
only two 
providers 
recalled and  
mentioned the 
IDSA 
guidelines; 
providers had 
Few providers 
relied on 
IDSA 
guideline in 
the treatment 
of 
uncomplicated 
UTIs. 
Good 
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widely differing  
opinions on the 
extent to which 
antibiotic 
resistance is a 
problem in their 
own practices 
Antibiotic 
Prescribing in 
New York State 
Medicare Part B 
Beneficiaries 
Diagnosed with 
Cystitis 
Between 2016 
and 2017  
Yu et al. (2020) 
Geographical 
antimicrobial 
prescribing 
patterns 
Retrospective, 
cohort study of 
Medicare Part B 
enrollees in 
New York State 
There were 
23,981 and 
26,677 
prescriptions 
written for 
cystitis across 
NYS in 2016 and 
2017. 
 
Data were 
stratified by sex. 
Annual 
prescriptions 
proportions were 
compared using  
𝑥2 test or Fisher’s 
exact test. 
IDSA 
guidelines: 
 
Nitrofurantoin, 
Trimethoprim-
sulfamethoxaz
ole, and 
fosfomycin 
were 
categorized as 
first-line 
agents. 
 
B-lactams and 
Fluoroquinolon
es are 
categorized as 
others. 
Counts and 
proportion were 
used to describe 
the year-
specific overall 
prescribing rate 
for each 
antibiotic 
category. 
The 𝑥2 tests 
were used to 
assess changes 
in antibiotic 
prescribing 
pattern, 
adherence to 
IDSA 
guidelines and 
quinolone 
prescribing rates 
from 2016 to 
2107. Heat 
maps were used 
to describe 
relative change 
between years 
for prescribing 
within specific 
regions. 
First-line 
antibiotic with 
Nitrofurantoin, 
TMP-SMX, 
and 
Fosfomycin 
prescription 
and B 
lactamase 
prescriptions 
increased, and 
fluoroquinolon
e use 
decreased in 
both older 
female and 
male adults. 
  
Good 
Effect of 5-Day 
Nitrofurantoin 
vs Single-Dose 
Fosfomycin on 
Clinical 
Resolution of 
Uncomplicated 
Lower Urinary 
Tract Infection 
in Women: a 
Randomized 
Clinical Trial. 
Huttner et al. 
(2018) 
Flow chart 
comparison 
of clinical 
and 
microbiologi
cal efficacy 
of 
Nitrofurantoi
n and 
Fosfomycin 
Multinational, 
open-label, 
analyst-
blinded, 
randomized 
clinical trial 
513 non-pregnant 
women aged 18 
years and older 
with symptoms 
of acute 
uncomplicated 
cystitis was 
conducted in 
Geneva, 
Switzerland from 
October 2013 to 
April 2017. 
Participants were 
recruited at 
hospital units and 
outpatient units. 
 
Primary 
outcome- 
clinical 
resolution in 
the 28 days 
following 
therapy 
 
Failure- need 
for additional 
of change in 
antibiotic 
treatment due 
to UTI or lack 
of efficacy 
 
Secondary 
outcomes- 
bacteriostatic 
response and 
incidence of 
adverse events. 
Statistical 
analysis with 
95% 
confidence 
interval. 
 
Primary and 
secondary 
outcomes were 
calculated 
using 
𝑥2 tests.  
At 28 days, 171 
of 244 (70%) of 
the 
Nitrofurantoin 
group and 139 
of 241 (58%) 
achieved 
clinical 
resolution. 
Microbiologic 
resolution 
occurred in 129 
of 175 (74%) 
and 103 of 163 
(63%) in the 
Nitrofurantoin 
and Fosfomycin 
groups, 
respectively. 
5-day 
Nitrofurantoin 
significantly 
has higher 
clinical and 
microbiologica
l resolution 
than single-
dose 
Fosfomycin, 
with few 
gastrointestina
l adverse 
events of 
nausea and 
vomiting for 
both groups. 
 
Good 
Preferential Use 
of 
Nitrofurantoin 
Over 
Fluoroquinolon
es for Acute 
Uncomplicated 
Cystitis and 
Outpatient 
Escherichia coli 
Resistance in an 
Integrated 
Healthcare 
System. 
Pedela RL, et al. 
(2017) 
Comparison 
of two time 
periods (by 
time series 
analysis)  
Retrospective 
pre-
intervention 
post-
intervention 
study.  
 
 
Urban setting in 
Colorado, 477-
bed hospital, 
emergency 
department and 
urgent care 
department, eight 
community 
health clinics, 
and 15 school-
based clinics. 
 
study included 
5,714 adults 
treated for acute 
cystitis and 11, 
Main 
outcomes- 
changes in 
Fluoroquinolon
es and 
Nitrofurantoin 
use and 
resistance 
among E. coli 
isolates. 
 
Secondary 
outcome-
change in total 
outpatient use, 
appropriatenes
s of 
Manual review 
of medical 
records of 100 
randomly 
selected 
patients 
prescribed 
Fluoroquinolon
es. Electronic 
laboratory data 
were expressed 
for E. coli 
isolates 
resistant to 
Fluoroquinolon
es or 
Time series 
analysis. Jan 
2003-Jan 2007 
when 
Fluoroquinolon
es were 
recommended 
as first-line 
therapy for 
acute 
uncomplicated 
UTI and 
Jul 2007- Dec 
2012 when 
Nitrofurantoin 
was 
recommended. 
After a change 
in the 
institutional 
guidelines, 
there was an 
immediate 
26% reduction 
in 
Fluoroquinolo
ne use and 
stabilization in 
Fluoroquinolo
ne resistant E. 
coli. There 
was an 
increased use 
of 
High 
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367 outpatient E. 
coli isolates. 
fluoroquinolon
e prescription, 
and occurrence 
of UTI-related 
clinical events 
in the 28 days 
after the index 
visit. 
Nitrofurantoin 
overtime. 
Autoregressive 
integrated 
moving 
average, 
correlation, and 
Chi-square test 
were for 
analyses. 
Nitrofurantoin 
use without a 
change in 
nitrofurantoin 
resistance.  
 
Evaluation of 
the trends and 
appropriateness 
of 
fluoroquinolone 
use in the 
outpatient 
treatment of 
acute 
uncomplicated 
cystitis at five 
family practice 
clinics. 
Robinson, et al. 
(2019) 
 
 
 
 
 
 
 
Retrospective 
Study 
19-64 YO 
women seen at 
five family 
medicine clinics 
and prescribed 
nitrofurantoin, 
ciprofloxacin, or 
levofloxacin for 
uncomplicated 
cystitis 
Appropriatenes
s of 
Nitrofurantoin 
or 
Fluoroquinolon
e treatment. 
Comorbidities, 
allergies, 
creatinine 
clearance, 
recent 
antibiotic use 
and urine 
culture data 
were used to 
determine 
appropriate 
empiric 
antibiotic 
treatment. 
 
Descriptive 
statistic, 
Pearson’s chi-
square or 
Fisher’s exact 
test, Student’s 
t-test, and 
multivariate 
logistic 
regression were 
used.  
Of the 567 
women included 
in the study, 
395 were given 
Nitrofurantoin 
and 172 were 
given 
Fluoroquinolon
es. 343 or 
86.8% and 18 or 
10.5% were 
appropriately 
prescribed 
Nitrofurantoin 
and 
fluroquinolones, 
respectively.  
For women 
inappropriately 
Fluoroquinolon
es, 15 or 87.8% 
lack 
contraindication 
to 
Nitrofurantoin. 
The study 
suggests the 
need for 
additional 
intervention 
and education 
to improve and 
decrease use 
of 
Fluoroquinolo
nes 
High 
Fosfomycin 
Trometamol 
versus 
Comparator 
Antibiotics for 
the Treatment 
of Acute 
Uncomplicated 
Urinary Tract 
Infections in 
Women: A 
Systematic 
Review and 
Meta-Analysis. 
Cai T et al. 
(2020) 
 Systematic 
Review and 
meta-analysis 
15 RCTs were 
included, with a 
total of 2,295 
female patients 
older than 18 
years old 
Microbial 
cure- 
eradication of 
infecting strain 
with no 
recurrent 
bacteriuria. 
 
Clinical cure-
complete 
resolution of 
symptoms at 
the end of 
treatment 
 
 
Safety 
outcomes- 
presence or 
absence of 
adverse effects 
95% CI, crude 
ORs and log 
ORs was 
calculated to 
analyze 
dichotomous 
data. Forest 
plot diagrams, 
funnel plot, and 
chi-square were 
used for sample 
sizes and 
variations 
among studies.  
The study 
included 15 
RCT which 
found no 
difference for 
microbial 
eradication 14 
RCT with total 
of 2, 052 
patients (OR 
1.03, 95% CI 
0.83-1.30, 
p=.09). No 
difference for 
safety outcome 
in 11 RCT in a 
total of 1, 816 
patients (OR 
1.17, 95% CI 
0.86-1.58, 
p=0.33). 
Fosfomycin 
trometamol is 
associated 
with high 
patient 
compliance 
and is as 
effective and 
safe in 
comparison to 
comparator 
antibiotic in 
the treatment 
of acute 
uncomplicated 
cystitis.  
 
High 
Improvement in 
adherence to 
antibiotic 
duration of 
therapy 
recommendatio
ns for 
uncomplicated 
cystitis: a quasi-
experimental 
study. 
 Quasi-
experimental 
study  
Women aged 18-
64 years who 
were prescribed 
Nitrofurantoin, 
TMX-SMT, or 
ciprofloxacin 
within seven days 
of encounter at 
five family 
medicine clinics. 
A stewardship 
intervention co
nsisting of 
revising/adding 
default 
prescribing 
instructions to 
targeted 
antimicrobials 
in an HER. 
One day in-
Pre and post 
intervention 
periods were 
assessed. Chi-
square or 
Fisher’s exact 
test, and 
Cochran 
Armitage Trend 
test were used 
to analyze 
A total of 787 
patients in the 
pre-intervention 
and 862 patients 
in post 
intervention 
were compared. 
After 
intervention, the 
adherence rate 
to the 
Clinics which 
received 
education 
increased 
adherence 
from 22.1% to 
58.8%; 
P<0.01. 
Revising/addin
g default 
prescribing 
High 
TREATMENT OUTCOMES OF ACUTE UNCOMPLICATED CYSTITIS  24 
Giancola SE, et 
al. (2019) 
service/ 
education was 
part of the 
interventions. 
 
Duration of 
treatment 
(DOT)- 5 days 
for 
Nitrofurantoin, 
3 days for 
TMX-SMT, 
fosfomycin 1 
dose, and 3 
days for 
Ciprofloxacin. 
nominal data. 
Student’s t-test 
was used to 
analyzed 
continuous 
data. Two 
tailed P-values 
≤0.05 were 
considered 
significant. 
recommended 
DOT for 
Nitrofurantoin 
increased from 
31% to 89% 
and an 
increased from 
22% to 60% for 
TMX-SMT. 
Adherence to 
recommended 
DOT increased 
in clinics which 
received 
education 
(33.7% vs 90.2 
%; P< 0.01). 
Clinics which 
did not received 
education 
increased 
adherence from 
22.1% to 
58.8%; P<0.01. 
instructions to 
targeted 
antimicrobials 
and their DOT 
in an EHR, 
and in-service, 
increased 
clinician 
adherence to 
uncomplicated 
cystitis first-
line antibiotic 
DOT 
guidelines. 
 
Systematic 
Review and 
Meta-analysis to 
Estimate the 
Antibacterial 
Treatment 
Effect of 
Nitrofurantoin 
for a Non-
Inferiority Trial 
in 
Uncomplicated 
Urinary Tract 
Infection. 
Mitrani-Gold 
FS, et al. (2020) 
 Systemic 
literature 
review and 
meta-analysis 
Search resulted in 
a total of 2048 
publications. Of 
these 76 met 
eligibility 
criteria. After 
inclusion and 
exclusion, twelve 
studies, including 
11 trials were 
included in meta-
analysis. 
Microbiologica
l response- AS 
per FDA 
guidance, 
defined as 
reduction of 
bacterial 
uropathogen 
recovered at 
study entry to 
<10³ or at by at 
least 1-log 
decrease 
(CFU/ml) on 
quantitative 
urine culture at 
the test-of-
cure-visit.
The study 
estimated the 
microbiological 
response rate 
for 
nitrofurantoin 
and placebo 
through cross 
trial 
comparison and 
inter-study 
heterogeneity 
was assessed 
with Cochran’s 
chi-square test. 
The overall 
microbiological 
response rate 
along with 95% 
confidence 
interval were 
presented in 
forest plots. 
The overall 
microbiological 
response (95% 
confidence 
interval) was 
0.766 (0.665, 
0.867) 
for nitrofurantoi
n and 0.342 
(0.288, 0.397) 
for placebo. 
The 
corresponding 
treatment 
effect estimate 
for 
Nitrofurantoin 
supports the 
conservative 
non-inferiority 
margin of 
12.5% and is 
consistent with 
the recently 
published 
FDA 
guidance. 
 
High 
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Table 2 
 
Evidence Synthesis Table  
 
Studies Design Sample Outcome/Findings 
Cost-Effectiveness Analysis of 
Fosfomycin for Treatment of 
Uncomplicated Urinary Tract 
Infections in Ontario. 
Perrault L, et al. (2017) 
 
Cost-minimization analysis, 
meta-analysis 
Data were obtained from 
Physician Services (2016), 
Ontario Case Costing Initiative, 
and Pharma Stat provincial data. 
The analysis revealed that the 
cost per patient for 
uncomplicated UTI treatment is 
similar for all 4 antibiotics, from 
$96.19 for sulfonamides to 
$105.12 for fosfomycin. 
Fosfomycin has lower resistance 
profile, safe, effective and offers 
a single dose regimen for 
treatment of uUTI, associated 
with high degree of compliance. 
Cost-effectiveness of antibiotic 
treatment of uncomplicated 
urinary tract infection in women: 
a comparison of four antibiotics. 
Sadler S, et al. (2017) 
Systems review, network meta-
analysis 
 
Probabilistic economic and 
deterministic sensitivity 
analyses. 
The systemic review identified 
11 studies that formed a 
connected evidence network 
meta-analysis. 
Based on recent estimates of 
trimethoprim resistance rates in 
England, a single 3 g dose of 
Fosfomycin is likely the most 
cost-effective treatment option 
for uncomplicated UTIs in 
women.  
Cost-effectiveness and budget 
impact of the management of 
uncomplicated urinary tract 
infection by community 
pharmacists. 
Sanyal et al. (2019) 
 
 
Prospective Study of community 
pharmacists in New Brunswick 
between June 2017 and April 
2018. 
 
Probabilistic analysis to evaluate 
impact of treatment strategies on 
cost and quality-adjusted-life-
months (QALMS) 
 
Cost-utility analysis 
The systemic review identified 
11 studies that formed a 
connected evidence network 
meta-analysis. 
The community pharmacist-
initiated and guided 
management was less costly and 
gave comparable QALMs 
compared to family and 
emergency physicians in 
prescribing Nitrofurantoin, 
TMP-SMX, or Fosfomycin for 
the treatment of uncomplicated 
UTIs. 
Qualitative Analysis of Primary 
Care Provider Prescribing 
Decisions for Urinary Tract 
Infections 
Grigoryan  et al.  (2019) 
 
 
 
 
Qualitative semi-structured 
interviews and thematic 
analysis. 
18 primary care providers 
practicing in two family 
medicine clinics in a large urban 
area in Texas, between July 
2017 and November 2017. 
Few providers relied on IDSA 
guideline in the treatment of 
uncomplicated UTIs. 
Antibiotic Prescribing in New 
York State Medicare Part B 
Beneficiaries Diagnosed with 
Cystitis Between 2016 and 
2017 
Yu et al. (2020) 
 
 
Retrospective, cohort study of 
Medicare Part B enrollees in 
New York State. 
There were 23,981 and 26,677 
prescriptions written for cystitis 
across NYS in 2016 and 2017. 
 
TMP-SMX, and Fosfomycin 
prescription and B lactamase 
prescriptions increased, and 
fluoroquinolone use decreased in 
both older female and male 
adults. 
 
The study suggests widespread 
prevalence of fluoroquinolone 
and B lactamase prescribing 
needs outpatient antimicrobial 
stewardship. 
 
Effect of 5-Day Nitrofurantoin 
vs Single-Dose Fosfomycin on 
Clinical Resolution of 
Uncomplicated Lower Urinary 
Tract Infection in Women: a 
Randomized Clinical Trial 
Huttner et al. (2018) 
Multinational, open-label, 
analyst-blinded, randomized 
clinical trial 
513 non-pregnant women aged 
18 years and older with 
symptoms of acute 
uncomplicated cystitis was 
conducted in Geneva, 
Switzerland from October 2013 
to April 2017. Participants were 
5-day Nitrofurantoin 
significantly has higher clinical 
and microbiological resolution 
than single-dose Fosfomycin, 
with few gastrointestinal adverse 
events of nausea and vomiting 
for both groups. 
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recruited at hospital units and 
outpatient units. 
 
Preferential Use of 
Nitrofurantoin Over 
Fluoroquinolones for Acute 
Uncomplicated Cystitis and 
Outpatient Escherichia coli 
Resistance in an Integrated 
Healthcare System. 
Pedela RL, et al. (2017) 
Retrospective pre-intervention 
post-intervention study.  
 
Urban setting in Colorado, 477-
bed hospital, emergency 
department and urgent care 
department, eight community 
health clinics, and 15 school-
based clinics. 
 
study included 5,714 adults 
treated for acute cystitis and 11, 
367 outpatient E. coli isolates. 
After a change in the 
institutional guidelines, there 
was an immediate 26% 
reduction in Fluoroquinolone 
use and stabilization in 
Fluoroquinolone resistant E. 
coli. There was an increased use 
of Nitrofurantoin use without a 
change in nitrofurantoin 
resistance.  
 
Evaluation of the trends and 
appropriateness of 
fluoroquinolone use in the 
outpatient treatment of acute 
uncomplicated cystitis at five 
family practice clinics. 
Robinson, et al. (2019) 
 
Retrospective Study 19-64 YO women seen at five 
family medicine clinics and 
prescribed nitrofurantoin, 
ciprofloxacin, or levofloxacin 
for uncomplicated cystitis 
Of the 567 women included in 
the study, 395 were given 
Nitrofurantoin and 172 were 
given Fluoroquinolones. 343 or 
86.8% and 18 or 10.5% were 
appropriately prescribed 
Nitrofurantoin and 
fluroquinolones, respectively.  
For women inappropriately 
Fluoroquinolones, 15 or 87.8% 
lack contraindication to 
Nitrofurantoin. 
Fosfomycin Trometamol versus 
Comparator Antibiotics for the 
Treatment of Acute 
Uncomplicated Urinary Tract 
Infections in Women: A 
Systematic Review and Meta-
Analysis. 
Cai T et al. (2020) 
Systematic Review and meta-
analysis 
15 RCTs were included, with a 
total of 2,295 female patients 
older than 18 years old 
Fosfomycin trometamol is 
associated with high patient 
compliance and is as effective 
and safe in comparison to 
comparator antibiotic in the 
treatment of acute 
uncomplicated cystitis.  
 
Improvement in adherence to 
antibiotic duration of therapy 
recommendations for 
uncomplicated cystitis: a quasi-
experimental study. 
Giancola SE, et al. (2019) 
Quasi-experimental study Women aged 18-64 years who 
were prescribed Nitrofurantoin, 
TMX-SMT, or ciprofloxacin 
within seven days of encounter 
at five family medicine clinics. 
Clinics which received 
education, with revised EHR, 
increased adherence from 22.1% 
to 58.8%; P<0.01. 
Revising/adding default 
prescribing instructions to 
targeted antimicrobials and their 
DOT in an EHR, and in-service, 
increased clinician adherence to 
uncomplicated cystitis first-line 
antibiotic DOT guidelines. 
 
Treatment Effect of 
Nitrofurantoin for a Non-
Inferiority Trial in 
Uncomplicated Urinary Tract 
Infection. 
Mitrani-Gold FS, et al. (2020) 
Systemic literature review and 
meta-analysis. 
Search resulted in a total of 2048 
publications. Of these 76 met 
eligibility criteria. After 
inclusion and exclusion, twelve 
studies, including 11 trials were 
included in meta-analysis. 
The corresponding treatment 
effect estimate for 
Nitrofurantoin supports the 
conservative non-inferiority 
margin of 12.5% and is 
consistent with the recently 
published FDA guidance. 
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Table 3 
Bias Assessment Using Cochrane Risk of Bias Tool 
                         Study             
D1 
       
D2 
      
D3 
      
D4 
      
D5 
  
Overall 
Cost-Effectiveness Analysis of Fosfomycin for Treatment of 
Uncomplicated Urinary Tract Infections in Ontario. 
Perrault L, et al. (2017 
      
Cost-effectiveness of antibiotic treatment of uncomplicated urinary 
tract infection in women: a comparison of four antibiotics. 
Sadler S, et al. (2017) 
      
Cost-effectiveness and budget impact of the management of 
uncomplicated urinary tract infection by community pharmacists. 
Sanyal et al. (2019) 
      
Qualitative Analysis of Primary Care Provider Prescribing 
Decisions for Urinary Tract Infections 
Grigoryan  et al.  (2019) 
      
Antibiotic Prescribing in New York State Medicare Part B 
Beneficiaries Diagnosed with Cystitis Between 2016 and 2017 
 
      
Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on 
Clinical Resolution of Uncomplicated Lower Urinary Tract 
Infection in Women: a Randomized Clinical Trial. 
Huttner et al. (2018) 
      
Preferential Use of Nitrofurantoin Over Fluoroquinolones for Acute 
Uncomplicated Cystitis and Outpatient Escherichia coli Resistance 
in an Integrated Healthcare System. 
Pedela RL, et al. (2017) 
      
Evaluation of the trends and appropriateness of fluoroquinolone use 
in the outpatient treatment of acute uncomplicated cystitis at five 
family practice clinics. 
Robinson, et al. (2019) 
 
      
Fosfomycin Trometamol versus Comparator Antibiotics for the 
Treatment of Acute Uncomplicated Urinary Tract Infections in 
Women: A Systematic Review and Meta-Analysis. 
Cai T et al. (2020) 
      
Improvement in adherence to antibiotic duration of therapy 
recommendations for uncomplicated cystitis: a quasi-experimental 
study. 
Giancola SE, et al. (2019) 
      
Systematic Review and Meta-analysis to Estimate the Antibacterial 
Treatment Effect of Nitrofurantoin for a Non-Inferiority Trial in 
Uncomplicated Urinary Tract Infection. 
Mitrani-Gold FS, et al. 
      
                                                                                                                            
Domains: 
D1: Bias due to randomization   
D2: Bias due to deviation from intended intervention                                                                  
D3: Bias due to missing data 
D4: Bias due to outcome measurement                               
D5: Bias due to selection of reported result 
 
 
 
Judgement: 
High             
                  Some concerns 
Low 
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Abbreviations 
AUC: acute uncomplicated cystitis 
DOT: duration of treatment 
EHR: electronic health records 
FDA: Food and drug administration 
FM: Fosfomycin 
FQ: Fluoroquinolones 
IDSA: Infectious Disease Society of America 
NTF: Nitrofurantoin 
NYS: New York State 
PCP: Primary care provider 
QALM: quality-adjusted-life-months 
RCT: Randomized Control Trial 
SMX-TMP: sulfamethoxazole-trimethoprim 
UTI: urinary tract infection 
uUTI: uncomplicated urinary tract infection 
                                                                                                                                                                                         
